Cornea | Ophthalmology Innovation Source

Alcon’s Plan For WaveTec’s ORA System

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 028″] Alcon’s Warner, Tom Frinzi Discuss the WaveTec Vision Acquisition Details. Podcast Guest Tom Frinzi Thomas Frinzi is Senior Vice President of Abbott’s vision business, which includes a broad ophthalmology portfolio across the areas of cataracts, refractive surgery (LASIK) and eye health products. Prior to joining Abbott, Mr. Frinzi held a…

Eleven’s Celniker Talks Leadership, Public Markets & Phase III Dry Eye Trials

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 021″] Eleven Biotherapeutics capitalized on exciting technology and promising clinical results for its lead dry eye product to stage a successful IPO in 2014. Abbie C. Celniker, PhD, President and CEO, talks frankly about her leadership style, dealing with public investors and how she’s managing high expectations for lead product EBI-005.…

TearScience CEO & Co-Founder Willis Explains Dry Eye Disease’s Emergence

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 019″] TearScience CEO & Co-Founder Tim Willis discusses the emergence of dry eye disease and details how his company’s diagnostic and treatment for a source of the condition could help meet the increasing interest from physicians and patients. Podcast Guest Tim Willis Mr. Willis has more than 35 years of medical…

Assort

Assort is a surgical management system that has insight, hindsight, and foresight, explained Assort Pty. Ltd.’s CEO Noel Alpins, MD. It can be used to analyze all ophthalmic parameters, including intraocular pressure and visual acuities. Assort uses the Alpins method to plan astigmatism surgery and analyze outcomes. Part of the Assort system, the iAssort software,…

i-Optics

[creativ_media type=”vimeo” url=”https://vimeo.com/111856584″] Presenter: Jeroen Cammeraat Jeroen Cammeraat is CEO of i-Optics and investor in the company since 2010. A serial entrepreneur and Senior Executive with 20+ years of global experience in the medical technology and life sciences market. View Full Profile

Avedro

Avedro’s KXL® System for accelerated cross-linking, as well as a family of riboflavin products, have been commercially available since 2010. Refractive correction pioneer and veteran David Muller, PhD, President & CEO, discussed the company’s most recent activities, expressing excitement about Avedro’s PiXL, a non-invasive refractive correction procedure, which uses only eye drops and light. Among other…

TearScience

TearScience Inc. CEO and Co-Founder Tim Willis emphasized that his company was founded for a single reason: to be the evaporative dry eye expert, and to develop a system to identify, diagnose, and treat Meibomian Gland Dysfunction, the root cause behind 90% of dry eye cases. He introduced for the first time TearScience’s LipiView II.…

Kala Pharmaceuticals Offers Glimpse Into Preclinical Pipeline

Kala Pharmaceutical Inc. is moving its proprietary Lotoprednol Etaobnate Mucus Penetrating Particle (LE-MPP) platform through a host of trials, Interim President and CBO Charlie McDermott reported. Animal investigations showed that LE-MPP retained approximately 10 times the concentration of the agent on the ocular surface at one hour than either lotoprednol etabonate nanoparticle or suspension alone,…

Panoptes Developing Inhibitor For Local Treatments In Ocular Disease

Panoptes Pharma GmhB is developing PP-001, a dihydroorotate dehydrogenase (DHODH) inhibitor for local treatments in ocular disease, Co-Founder and CEO Franz Obermayr, PhD, told the OIS gathering. Preclinical investigation is focusing on use for intravitreal and oral administration for posterior uveitis, but Panoptes is also researching topical applications for anterior uveitis, dry eye and viral…

How Alcon & Google Could Change The Contact Lens

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 013″] At the recent Ophthalmology Innovation Summit in Chicago, Google and Alcon executives shared the origins and potential outcomes of the partnership between the two companies. Initially, they hope to develop a contact lens capable of measuring the wearer’s glucose levels but future applications are even bolder.

Hear How Avedro’s Muller Is Building A Cross-Linking Powerhouse

Episode 007 CEO David Muller, maps out Avedro’s designs to dominate the corneal cross-linking market and potentially change the game of vision correction. Podcast Guest David Muller, PhD Dr. Muller recognized the potential of using advanced methods to gently reshape the cornea and in 2007 founded Avedro, Inc., where he serves as the CEO. Under…

Avedro Broadens Cross-Link Product Line

Corneal collagen cross-linking has been a vexing specialty for US-based companies trying to guide a product through a cautious FDA. But Massachusetts-based Avedro Inc., continues to establish a meaningful portfolio in the space through deals like the acquisition of Switzerland-based IROC Innocross AG. Avedro acquired the assets of IROC Innocross, which was the first company…